Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

Scleroderma, Systemic Clinical Trial

Official title:

Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00333437
• Other study ID #: CEL371
• Status: Completed
• Phase: N/A
• First received: June 2, 2006
• Last updated: September 23, 2013
• Start date: May 2006
• Est. completion date: January 2009

Study information

• Verified date: September 2013
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Description:

The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic sclerosis (SSc). This study utilizes a prospective, open-label, experimental design.

Primary Hypothesis: The alveolitis in patients with SSc, as defined by decreased forced vital capacity (FVC), bronchoalveolar lavage (BAL), and High Resolution Chest Tomography (HRCT) is responsive to 1 year of daily mycophenolate mofetil therapy.

Secondary Hypothesis: Quality of life, six-minute walk and single-breath diffusing capacity for carbon monoxide (DLCO) improve in patients with SSc mediated alveolitis after therapy with mycophenolate mofetil. This response to therapy is associated with a change in the inflammatory cytokine profile present in BAL fluid.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• To participate in this study, patients must first undergo a BAL and HRCT. To be eligible to undergo HRCT and BAL (under the purview of this trial), prospective patients must meet the following criteria:

• Aged 21-70.

• Negative pregnancy test (with a sensitivity of at least 50 mIU/mL) for females of child-bearing potential

• All patients must fulfill the criteria for SSc by American College of Rheumatology (ACR) criteria (Subcommittee for Scleroderma Criteria 1980).

• FVC < 85% of predicted.

• SSc for no more than 7 years with onset defined as the date of the first non-Raynaud manifestation.

• Patients may have limited (cutaneous thickening distal but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger 1995).

• Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.

• To be eligible to take study medication, the patient must meet not only the criteria above, but also must have = 3.0% neutrophils or = 2.0% eosinophils in screening BAL fluid and/or ground glass opacification on HRCT.

• Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 1 week before beginning therapy. CellCept therapy will not be initiated until a report of a negative pregnancy test has been obtained.

• Effective contraception must be used before beginning CellCept therapy, during therapy, and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy does occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.

Exclusion Criteria:

• FVC < 45% of predicted or DLCO (corrected for hemoglobin [Hgb] but not for alveolar volume) < 35% of predicted (suggestive of severe, probably irreparable, disease).

• Leukopenia (white blood cell count < 4000) or thrombocytopenia (platelet count < 100,000).

• Serum creatinine = 2.0 mg/dl.

• Pregnancy, breast feeding, unreliability, drug abuse, or chronic debilitating disease.

• Uncontrolled congestive heart failure.

• Active infection of the lung, or elsewhere, whose management would be compromised by mycophenolate mofetil.

• Prior treatment for alveolitis with mycophenolate mofetil or prior or current treatment for alveolitis with: D-penicillamine, methotrexate, colchicine, Potaba, or azathioprine.

• Other serious concomitant medical illness (e.g., cancer).

• Forced expiratory volume in 1 second (FEV1)/FVC ratio < 65%.

• If of childbearing potential, failure regularly to be employing two reliable means of contraception (i.e., condom, abstinence, intrauterine device (IUD), tubal ligation, vasectomy)

• Pulmonary hypertension (defined as an estimated systolic blood pressure (SBP) = 35 mmHg measured by echocardiogram).

• Smoking of cigars, pipes, or cigarettes during the past 6 months.

• Clinically significant abnormalities on chest x-ray or HRCT scan other than interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection).

• Use of prednisone (or equivalent) in doses > 10 mg per day.

• Does not have = 3.0% neutrophils or = 2.0% eosinophils on screening BAL fluid and does not have ground glass opacification on HRCT.

• Unable to take oral medication.

• Not able to comply with study procedures in the opinion of the investigator.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Scleroderma, Diffuse
• Scleroderma, Localized
• Scleroderma, Systemic

Intervention

Drug:
• Mycophenolate mofetil

Locations

Country	Name	City	State
United States	UCSF, 400 Parnassus Ave	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Roche Pharma AG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline in Forced Vital Capacity (FVC)	compare pre- and post-therapy FVC (post- minus pre-). Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.	Baseline, 12 months	No
Secondary	Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)	BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.	Baseline, 12 months	No
Secondary	Change in Shortness of Breath (Self-reported)	Participants reported frequency of shortness of breath experienced with exertion	Baseline, 12 months	No
Secondary	Mean Change in Six Minute Walk Distance	Comparison of 6-minute walk distance before beginning and after completing study therapy	12 months	No
Secondary	Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)	DLCO was measured before beginning and after completion of study therapy	12 months	No

External Links

•   UCSF PULMONARY & CRITICAL CARE MEDICINE, INTERSTITIAL LUNG DISEASE CENTER OF EXCELLENCE